Fleischner学会立场文件:CT偶然发现的间质性肺异常
Fleischner学会发布立场文件,针对无临床怀疑间质性肺病患者CT上偶然发现的间质性肺异常(ILA)进行定义标准化和术语统一。ILA在吸烟者中占4-9%、非吸烟者中占2-7%,与影像学进展、死亡率增加及化疗和手术并发症风险相关。管理需区分临床显著间质性肺病与亚临床ILA,尤其识别更易进展和死亡的胸膜下纤维化亚型。
要点
- ILA指无临床怀疑间质性肺病患者CT上可能符合间质性肺病的特定表现。
- 胸膜下纤维化亚型更易进展且与死亡率相关,需重点识别。
- 管理需区分临床显著间质性肺病与亚临床ILA。
核心结论
- ILA与影像学进展、死亡率增加及化疗和手术并发症风险相关,管理需区分临床显著间质性肺病与亚临床ILA。
研究设计与样本
- Fleischner学会多学科立场文件,基于文献汇总与专家共识。
主要发现
- ILA在吸烟者中占4-9%,在非吸烟者中占2-7%。
- 胸膜下纤维化亚型更易进展且与死亡率相关。
关键数值与推荐
- ILA定义为无临床怀疑间质性肺病患者CT上可能符合间质性肺病的特定表现。
临床怎么用
- 需识别胸膜下纤维化亚型以评估进展和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The term interstitial lung abnormalities refers to specific CT findings that are potentially compatible with interstitial lung disease in patients without clinical suspicion of the disease. Interstitial lung abnormalities are increasingly recognised as a common feature on CT of the lung in older individuals, occurring in 4-9% of smokers and 2-7% of non-smokers. Identification of interstitial lung abnormalities will increase with implementation of lung cancer screening, along with increased use of CT for other diagnostic purposes. These abnormalities are associated with radiological progression, increased mortality, and the risk of complications from medical interventions, such as chemotherapy and surgery. Management requires distinguishing interstitial lung abnormalities that represent clinically significant interstitial lung disease from those that are subclinical. In particular, it is important to identify the subpleural fibrotic subtype, which is more likely to progress and to be associated with mortality. This multidisciplinary Position Paper by the Fleischner Society addresses important issues regarding interstitial lung abnormalities, including standardisation of the definition and terminology; predisposing risk factors; clinical outcomes; options for initial evaluation, monitoring, and management; the role of quantitative evaluation; and future research needs.
引用
- Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020. PMID: 32649920. doi:10.1016/S2213-2600(20)30168-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。